已收盘 12-19 16:00:00 美东时间
-0.250
-1.71%
Scilex Holding Company announced the deferral of its previously announced dividend record date to a later date, with the ability to change or revoke the dividend. The company focuses on non-opioid pain management products and has several commercial products and pipeline candidates targeting acute and chronic pain, neurodegenerative, and cardiometabolic diseases.
06-23 20:50
Denali Capital Acquisition Corp. deposited $874.78 into its trust account to extend its business combination deadline to July 11, 2025. The funds were provided through a $180,000 convertible promissory note from Scilex Holding Company, with no interest, repayable upon business combination or liquidation. The note is convertible into Class A shares at $10 per share. Remaining funds may extend the deadline further.
06-12 00:30
Scilex Holding Company announced the publication of GLOPERBA® dosing adjustments for patients with renal impairment in a peer-reviewed journal, providing optimized dosing to enhance safety and efficacy in gout flare prevention.
06-05 16:05
StealthGas Inc. will release its Q1 2025 financial results on May 28, 2025, followed by a conference call at 10:00 am ET. Participants can register via the provided link to access the call. A live and archived webcast will also be available on the company's website.
05-22 13:59
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
2024-09-05 21:02
10:19 AM EDT, 09/03/2024 (MT Newswires) -- Scilex (SCLX) unit Semnur Pharmaceuticals and Denali Capital Acquisition (DECA) said Tuesday they have signed an agreement for a planned merger which provides for a pre-transaction equity value of Semnur at $2.5 billion. Upon closing of the deal, the combin...
2024-09-03 22:19
09:47 AM EDT, 08/29/2024 (MT Newswires) -- Scilex Holding (SCLX) said Thursday that the US Food and Drug Administration has approved the company's supplemental new drug application for precision dosing of the Gloperba label. Gloperba is an FDA-approved liquid formula of colchicine, an anti-gout medi...
2024-08-29 21:47
09:49 AM EDT, 08/21/2024 (MT Newswires) -- Scilex Holding (SCLX) said Wednesday that it is set to receive a new patent from the US Patent and Trademark Office later this year covering its claims related to acute pain treatment. The company said the US Patent and Trademark Office "has allowed numerou...
2024-08-21 21:49